Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
A phase 1/2a trial has been conducted to evaluate the safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies. The trial's results are being reported, although the specifics of the findings are not detailed in the available information. The study apparently assessed both the safety and antiviral efficacy of this particular combination of antibodies.